Home » Stocks » VOR

Vor Biopharma, Inc. (VOR)

Stock Price: $21.27 USD -1.00 (-4.49%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $21.40 +0.13 (0.61%) Jun 11, 7:14 PM
Market Cap 789.79M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 22.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $21.27
Previous Close $22.27
Change ($) -1.00
Change (%) -4.49%
Day's Open 22.42
Day's Range 20.92 - 22.42
Day's Volume 71,639
52-Week Range 18.11 - 63.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targete...

2 weeks ago - GlobeNewsWire

Health Canada clears the CTA for VOR33 clinical trial

1 month ago - GlobeNewsWire

IND accepted for VOR33, Vor's lead eHSC product candidate for treatment of AML

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies f...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies f...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies fo...

4 months ago - GlobeNewsWire

Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the prici...

4 months ago - GlobeNewswire

Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

4 months ago - NASDAQ

Vor Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, according t...

5 months ago - Healio

About VOR

Vor Biopharma is a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure is through hematopoietic stem cell transplant (HSCT). Despite undergoing HSCT, approximately 40% of acute myeloid leukemia (AML) patients relapse and face an extremely poor prognosis, with two-year survival rates of less than 20%. The traditional tumor target ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Robert Ang, M.B.B.S.
Employees
92
Stock Exchange
NASDAQ
Ticker Symbol
VOR
Full Company Profile

Financial Performance

Financial Statements